Pfizer plans job cuts in Switzerland to reduce expenses
The cuts follow a broader downgrading of the drug manufacturer’s Swiss operations.
Drug Development
Boehringer’s Jascayd gains China’s NMPA approval for PPF
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Formycon and Zydus sign exclusive agreement for FYB206 supply
Health Canada approves Biogen’s Zurzuvae for PPD treatment
EC approves Roche’s Gazyva to treat active lupus nephritis
Inductive Bio gains $21m ARPA-H funds for drug prediction models
Viatris signs agreements with Biocon on $815m stake sale
